THEO-DUR Drug Patent Profile

When do Theo-dur patents expire, and what generic alternatives are available?

Theo-dur is a drug marketed by Schering and is included in seven NDAs.

The generic ingredient in THEO-DUR is theophylline. There are thirty-six drug master file entries for this compound. Twenty-eight suppliers are listed for this compound. Additional details are available on the theophylline profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Theo-dur

A generic version of THEO-DUR was approved as theophylline by RHODES PHARMS on September 1^st, 1982.

Summary for THEO-DUR

US Patents:	0
Applicants:	1
NDAs:	7
Raw Ingredient (Bulk) Api Vendors:	1
Patent Applications:	3,203
DailyMed Link:	THEO-DUR at DailyMed

US Patents and Regulatory Information for THEO-DUR

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Schering	THEO-DUR	theophylline	CAPSULE, EXTENDED RELEASE;ORAL	088022-001	Sep 10, 1985		DISCN	No	No
Schering	THEO-DUR	theophylline	TABLET, EXTENDED RELEASE;ORAL	085328-002	Approved Prior to Jan 1, 1982		DISCN	Yes	No
Schering	THEO-DUR	theophylline	CAPSULE, EXTENDED RELEASE;ORAL	087995-001	Sep 10, 1985		DISCN	No	No
Schering	THEO-DUR	theophylline	TABLET, EXTENDED RELEASE;ORAL	089131-001	Jun 25, 1986		DISCN	No	No
Schering	THEO-DUR	theophylline	CAPSULE, EXTENDED RELEASE;ORAL	088015-001	Sep 10, 1985		DISCN	No	No

THEO-DUR: Market Dynamics and Financial Trajectory

Last updated: February 19, 2026

THEO-DUR, a sustained-release formulation of theophylline, has experienced significant market shifts driven by patent expirations, generic competition, and evolving treatment paradigms for respiratory diseases. Its financial trajectory reflects these changes, transitioning from a blockbuster revenue generator to a mature product facing intense price pressure.

What is THEO-DUR's Historical Market Position?

Theophylline, the active pharmaceutical ingredient in THEO-DUR, has been a cornerstone in the management of asthma and chronic obstructive pulmonary disease (COPD) for decades. THEO-DUR, introduced by Key Pharmaceuticals (later acquired by Schering-Plough, then Merck & Co.), represented a significant advancement in oral theophylline delivery. Its sustained-release mechanism allowed for less frequent dosing and more stable serum concentrations compared to immediate-release formulations, aiming to improve patient adherence and reduce the frequency of adverse events.

The product achieved substantial market penetration due to its efficacy in bronchodilation and its relatively low cost compared to newer inhaled therapies, particularly in its early years. It was a widely prescribed medication, generating significant revenue for its manufacturers. The peak sales figures for THEO-DUR were substantial, though precise historical data is not readily available in public databases, industry reports from the 1980s and 1990s indicated it was a leading respiratory medication.

How Have Patent Expirations Impacted THEO-DUR?

The expiration of key patents protecting THEO-DUR’s formulation and manufacturing processes was a critical inflection point. While the exact dates of all patents are not publicly consolidated, the primary patents for theophylline formulations began expiring in the late 1980s and early 1990s. This opened the door for generic manufacturers to enter the market.

The loss of market exclusivity allowed for the introduction of multiple generic versions of theophylline sustained-release products. These generic competitors offered a significantly lower price point, directly impacting THEO-DUR’s market share and pricing power. The pharmaceutical market typically sees a steep decline in the revenue of a branded drug following the introduction of generic alternatives. For THEO-DUR, this meant a reduction in its revenue base as healthcare providers and payers shifted towards more cost-effective generic options.

What is the Current Competitive Landscape for THEO-DUR?

The current competitive landscape for THEO-DUR is characterized by robust generic penetration. The market is populated by numerous manufacturers offering bioequivalent versions of theophylline sustained-release tablets. Key market players in the generic theophylline space include companies like Teva Pharmaceuticals, Mylan (now Viatris), and numerous smaller regional manufacturers.

The therapeutic class of bronchodilators, which includes theophylline, has also seen the rise of more advanced and targeted therapies. Inhaled corticosteroids (ICS), long-acting beta-agonists (LABAs), long-acting muscarinic antagonists (LAMAs), and combination inhalers have become the first-line treatments for many asthma and COPD patients. These newer agents often offer improved safety profiles, greater efficacy, and more convenient administration routes for certain patient populations.

This evolution in treatment guidelines has reduced the overall market size for oral theophylline. While it remains a viable option for specific patient groups, such as those who have failed other therapies or for whom cost is a primary barrier, its role has become more niche.

What is THEO-DUR's Projected Financial Trajectory?

The projected financial trajectory for THEO-DUR, and by extension branded theophylline sustained-release products, is one of continued decline in revenue and market share. The product is now considered a mature, off-patent medication.

• Revenue Decline: The primary driver of revenue decline will be the ongoing price erosion due to generic competition. The average selling price of theophylline sustained-release products is significantly lower than during its patent-protected period.
• Market Share Stagnation/Reduction: The increasing adoption of newer, guideline-recommended respiratory therapies will likely lead to further erosion of market share, even among the remaining indications for theophylline.
• Limited R&D Investment: Due to its mature status and generic competition, there is minimal incentive for significant research and development investment in new formulations or indications for THEO-DUR by its current or potential manufacturers. Investment is typically focused on the generic manufacturing and distribution of the product.
• Geographic Variations: Revenue may persist longer in markets with less advanced healthcare systems, lower generic penetration, or where cost is a more dominant factor in prescribing decisions. However, global trends are towards the adoption of newer therapies.

The financial performance of THEO-DUR will be largely dictated by the volume of prescriptions filled by generic equivalents and the wholesale acquisition costs of these generics, which are subject to intense bidding among pharmacy benefit managers and distributors.

What Regulatory and Pricing Factors Affect THEO-DUR?

Regulatory and pricing factors are critical in shaping THEO-DUR’s market performance.

• Bioequivalence Requirements: Regulatory bodies like the U.S. Food and Drug Administration (FDA) require generic theophylline sustained-release products to demonstrate bioequivalence to the reference listed drug (RLD), which was likely THEO-DUR. This ensures therapeutic interchangeability. The FDA's Orange Book lists approved drug products with therapeutic equivalence evaluations.
• Pricing Pressures: The dominant pricing factor is generic competition. Healthcare payers, including government programs (e.g., Medicare Part D, Medicaid) and private insurers, actively promote the use of generics through formulary placement, co-payment structures, and preferred drug lists. This exerts downward pressure on the prices of all theophylline sustained-release products.
• Reimbursement Policies: Reimbursement policies often favor the lowest-cost therapeutically equivalent option, which is typically a generic theophylline product. Manufacturers of branded THEO-DUR, if still actively marketing it, would face significant challenges in securing favorable formulary placement.
• Off-Label Use and Guidelines: While primarily indicated for asthma and COPD, theophylline has historically seen off-label uses. However, current clinical guidelines from organizations like the Global Initiative for Asthma (GINA) and the GOLD (Global Initiative for Chronic Obstructive Lung Disease) report generally do not prioritize theophylline as a first-line or even second-line therapy for most patients, impacting prescription volumes.
• Post-Marketing Surveillance: Like all pharmaceuticals, THEO-DUR and its generics are subject to post-marketing surveillance for safety and efficacy. Any significant adverse event findings could impact its prescribing.

The market for THEO-DUR operates within a highly competitive, price-sensitive generic drug environment, heavily influenced by payer policies and evolving clinical practice.

What is the Impact of Clinical Guidelines on THEO-DUR's Usage?

The evolution of clinical guidelines for respiratory diseases has significantly curtailed the optimal therapeutic positioning of THEO-DUR and other theophylline formulations.

• Shift to Inhaled Therapies: Major guidelines, such as those published by GINA for asthma and GOLD for COPD, have increasingly emphasized the use of inhaled therapies as the foundation of treatment. These include:
  • Inhaled Corticosteroids (ICS): For asthma, ICS are recommended for most patients to control inflammation.
  • Long-Acting Beta-Agonists (LABAs): Often used in combination with ICS for asthma and as maintenance therapy for COPD.
  • Long-Acting Muscarinic Antagonists (LAMAs): Primarily used for COPD management.
  • Combination Inhalers: Offering multiple bronchodilators or bronchodilators with ICS provide convenient, multi-modal treatment for moderate to severe disease.
• Theophylline's Declining Role: Theophylline is typically relegated to adjunctive or rescue therapy for specific patient profiles:
  • Patients who have not achieved symptom control with standard inhaled therapies.
  • Patients who cannot afford or tolerate newer inhaled medications.
  • In some instances, for nocturnal asthma symptoms, although newer agents are also effective.
• Safety Concerns: While THEO-DUR's sustained-release formulation aimed to mitigate some risks, theophylline has a narrow therapeutic index. Therapeutic drug monitoring (TDM) is often required to maintain serum concentrations within the target range (typically 5-15 mcg/mL for long-term control) to avoid toxicity, which can include nausea, vomiting, headache, seizures, and arrhythmias. This monitoring requirement adds complexity and cost, further disincentivizing its use compared to simpler inhaled therapies.
• GINA and GOLD Recommendations: The GINA report has progressively de-emphasized theophylline, reserving it for carefully selected patients. Similarly, the GOLD report positions inhaled bronchodilators as the primary treatment for COPD, with theophylline considered an option for symptomatic patients who have not responded adequately to other therapies or when cost is a significant factor.

These shifts in guideline recommendations directly translate to reduced prescription volumes for THEO-DUR and its generic equivalents as healthcare providers adhere to evidence-based, preferred treatment modalities.

What are the Key Manufacturing and Supply Chain Considerations?

The manufacturing and supply chain for THEO-DUR operate within the dynamics of generic pharmaceutical production.

• Active Pharmaceutical Ingredient (API) Sourcing: Theophylline API is a well-established commodity. Manufacturers source it from global suppliers, primarily in China and India, where production costs are competitive. The quality and consistency of API are paramount, subject to stringent regulatory oversight.
• Formulation and Manufacturing: The sustained-release formulation requires specific manufacturing processes to ensure consistent drug release profiles. Generic manufacturers must replicate these processes to meet bioequivalence standards. Manufacturing facilities are subject to Good Manufacturing Practices (GMP) regulations.
• Scale of Production: Production volumes are driven by market demand, which for theophylline sustained-release has stabilized or declined. Manufacturers operate at scales that optimize cost-efficiency for this mature product.
• Distribution Channels: THEO-DUR and its generic equivalents are distributed through wholesalers and directly to pharmacies, hospitals, and long-term care facilities. Supply chain efficiency and reliable delivery are critical.
• Inventory Management: Generic drug manufacturers manage inventory to meet fluctuating demand and avoid stockouts, balancing production runs with shelf-life considerations.
• Cost Optimization: Continuous cost optimization in manufacturing and supply chain logistics is essential for generic manufacturers to remain competitive in a low-margin market. This includes efficient sourcing, streamlined production, and optimized distribution networks.
• Regulatory Compliance: All aspects of manufacturing and distribution must comply with regional and national pharmaceutical regulations, including inspections and audits by health authorities.

The supply chain for THEO-DUR is characterized by a mature, competitive generic environment where cost efficiency and regulatory compliance are paramount.

Key Takeaways

THEO-DUR, once a leading respiratory therapy, has transitioned to a mature, off-patent product facing significant revenue decline due to generic competition and evolving clinical guidelines. The market is dominated by lower-cost generic theophylline sustained-release formulations. Newer inhaled therapies are now the preferred first-line treatments for asthma and COPD, relegating theophylline to niche applications. The financial future of THEO-DUR and its equivalents is characterized by continued price erosion and reduced market share, with manufacturing and supply chains focused on cost efficiency within a regulated generic drug environment.

---

FAQs

1. What are the primary therapeutic indications for theophylline sustained-release products like THEO-DUR? Theophylline sustained-release products are primarily indicated for the management of symptoms of asthma and chronic obstructive pulmonary disease (COPD).

2. How does the bioavailability of generic theophylline sustained-release products compare to branded THEO-DUR? Regulatory agencies like the FDA require generic versions to demonstrate bioequivalence to the reference listed drug, meaning they deliver the same amount of active ingredient into the bloodstream over the same period. Therefore, they are considered therapeutically equivalent.

3. What are the main reasons for the decline in THEO-DUR's market share? The decline is primarily due to patent expiration leading to widespread generic competition, and the development and adoption of more advanced, often inhaled, respiratory therapies that are now considered first-line treatments by clinical guidelines.

4. What is the typical price difference between branded THEO-DUR and its generic equivalents? Generic equivalents of THEO-DUR are generally priced significantly lower than the original branded product, often representing a fraction of the cost, due to intense competition in the generic drug market.

5. Are there any ongoing research and development efforts related to THEO-DUR? Given its status as a mature, off-patent drug, significant R&D for new formulations or indications of THEO-DUR is unlikely. Current efforts would primarily focus on optimizing generic manufacturing processes and ensuring supply chain efficiency.

---

Citations

[1] Food and Drug Administration. (n.d.). Approved Drug Products with Therapeutic Equivalence Evaluations (Orange Book). Retrieved from [FDA Website] (Specific URL for Orange Book search would be used here if accessible).

[2] Global Initiative for Asthma. (2023). Global Strategy for Asthma Management and Prevention. Retrieved from [GINA Website] (Specific URL for current GINA report would be used).

[3] GOLD COPD. (2023). Global Strategy for the Diagnosis, Management and Prevention of COPD. Retrieved from [GOLD Website] (Specific URL for current GOLD report would be used).